IGF1R and breast carcinoma: In summary, these findings demonstrate that IGF-1R signaling not only drives tumorigenesis but also serves as a critical mediator of therapeutic resistance across multiple breast cancer subtypes, highlighting the potential of targeting IGF-1R or its downstream pathways as a strategy to overcome resistance and improve patient outcomes.